法国生物制药公司Abivax S.A.（ABVX）今日盘前股价大涨19.7%，引发市场广泛关注。
消息面上，据法国媒体La Lettre报道，美国制药巨头礼来（LLY）拟以150亿欧元（约合175亿美元）的价格收购Abivax，这一报价几乎是该公司当前市值的两倍。Abivax的核心药物obefazimod（用于治疗溃疡性结肠炎）在三期临床试验中表现优异，使其成为极具吸引力的并购目标。
分析师指出，若收购成功，Abivax的合理股价可能达到每股150至250欧元，反映了控制权溢价、协同效应及晚期炎症性肠病（IBD）口服药物的战略价值。此前，该公司股价曾因obefazimod的积极试验数据单日暴涨500%以上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.